| |
Financial Year 2007 - 2008
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2006
| (Rs.in Million) |
Quarter ended
31st March |
Sl.No |
Particulars |
Nine months ended 31st December 2005Audited) |
Year ended
31st March |
| 2006(Audited) |
2005( Un audited) |
|
|
|
2006(Audited) |
2005(Audited) |
| 1,610.90 |
1,584.00 |
1 |
Sales (net) |
5,060.46 |
6,671.36 |
6,367.62 |
| 1,289.66 |
673.73 |
|
- Exports |
2,670.22 |
3,959.88 |
3,410.07 |
| 321.24 |
910.27 |
|
- Domestic |
2,390.24 |
2,711.48 |
2,957.55 |
| 66.17 |
38.24 |
2 |
Income from Potential patent infringment suit |
202.22 |
268.39 |
38.24 |
| 98.53 |
7.77 |
3 |
Other Income |
1,218.73 |
1,317.26 |
117.04 |
| 1,281.47 |
1,149.14 |
4 |
Total Expenditure |
4,242.24 |
5,523.71 |
4,499.84 |
114.15 |
(43.17) |
|
a) (Increase) / Decrease in Stock |
(281.98) |
(167.83) |
(116.10) |
| 793.01 |
838.91 |
|
b) Materials Consumed |
3,236.83 |
4,029.84 |
3,279.58 |
| 117.27 |
102.82 |
|
c) Staff Cost |
362.73 |
480.00 |
369.64 |
| 257.04 |
250.58 |
|
d) Other Expenditure |
924.66 |
1,181.70 |
966.72 |
| 494.13 |
480.87 |
5 |
Profit before R&D, Interest & Depreciation(1+2+3-4) |
2,239.17 |
2,733.30 |
2,023.06 |
| 120.77 |
50.46 |
6 |
Research and Development Expenditure |
190.42 |
311.19 |
159.35 |
| 27.58 |
8.38 |
7 |
Interest |
53.92 |
81.50 |
62.77 |
| 55.15 |
57.61 |
8 |
Depreciation |
168.27 |
223.42 |
191.00 |
| 290.63 |
364.42 |
9 |
Profit before Tax (5-6-7-8) |
1,826.56 |
2,117.19 |
1,609.94 |
(16.42) |
78.13 |
10 |
Provision for Tax |
309.81 |
293.39 |
307.27 |
| 307.05 |
286.29 |
11 |
Profit after Tax (9-10) |
1,516.75 |
1,823.80 |
1,302.67 |
| 307.26 |
299.47 |
12 |
Equity Capital |
306.47 |
307.26 |
299.47 |
| - |
- |
13 |
Reserves excluding revaluation reserves |
- |
8,333.87 |
5,934.09 |
|
|
14 |
E.P.S (Face value - Rs.2/-) |
|
|
|
2.00 |
1.91 |
|
- Basic - Not annualised |
10.13 |
- |
- |
8.00 |
7.64 |
|
Annualised |
11.98 |
12.11 |
8.90 |
1.96 |
1.89 |
|
- Diluted - Not annualised |
9.89 |
- |
- |
7.84 |
7.56 |
|
Annualised |
11.69 |
11.89 |
8.87 |
|
|
15 |
Aggregate of Non Promoters' Shareholding |
68750750 |
49907420 |
|
Number of shares - Face value of Rs.2 / - each. |
55404520 |
68750750 |
49907420 |
44.75% |
33.34% |
|
Percentage of Shareholding |
36.16% |
44.75% |
33.34% |
|
Notes :
| 1 |
The above results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 10th June 2006. |
| 2 |
The activities of the Company relate to only one business segment i.e. Pharmaceuticals. |
| 3 |
During the quarter, the company completed strategic investments in Fine Chemical Corporation, South Africa, Mchem Group, China and Concord Biotech Limited, India. |
| 4 |
The Board of Directors recommended a Dividend of Rs.1.20 / share (60%). |
| 5 |
394,330 Equity shares of Rs.2/- each at a premium of Rs.141.13 were allotted during the quarter, on exercise of stock options under the Employees Stock Option Scheme. |
| 6 |
Provision for tax includes Current tax, Deferred tax and Fringe benefit tax and is net of excess provision written back. |
| 7 |
Summary of Investor Complaints
Opening : Nil , Received during the quarter :2 , Resolved :2 , Closing : Nil |
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 10th June 2006 |
Sd/-
N. PRASAD
Executive Chairman |
|
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD-03
AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED
31stMARCH 2006
|
Sl.No |
Particulars |
Quarter ended
31st March 2006 (Audited) |
Year ended
31st March 2006
(Audited) |
01 |
Sales (net) |
3,928.04 |
11,586.15 |
02 |
Income from Potential patent infringment suit |
66.17 |
268.39 |
03 |
Other Income |
136.98 |
1,400.81 |
04 |
Total Expenditure |
3,356.08 |
9,876.01 |
|
a) (Increase) / Decrease in Stock |
(11.29) |
(293.27) |
|
b) Materials Consumed |
2,313.90 |
7,070.38 |
|
c) Staff Cost |
506.78 |
1,210.36 |
|
d) Other Expenditure |
546.69 |
1,888.54 |
05 |
Profit before R&D, Interest & Depreciation(1+2+3-4) |
775.11 |
3,379.34 |
06 |
Research and Development Expenditure |
147.21 |
393.73 |
07 |
Interest |
129.54 |
268.84 |
08 |
Depreciation |
104.03 |
335.05 |
09 |
Profit before Tax (5-6-7-8) |
394.33 |
2,381.72 |
10 |
Provision for Tax |
22.79 |
376.09 |
11 |
Profit after Tax before Minority Interest and share in Associates (9-10) |
371.54 |
2,005.63 |
12 |
Less : Minority Interest |
(6.16) |
(6.16) |
13 |
Less : Share of loss in Associate |
(3.70) |
(7.42) |
14 |
Net Profit (11-12-13) |
361.68 |
1,992.05 |
15 |
Equity Capital |
307.26 |
307.26 |
16 |
Reserves excluding revaluation reserves |
- |
9,420.63 |
17 |
E.P.S (Face value - Rs.2/-) |
|
|
|
- Basic - Not annualised |
2.36 |
- |
|
Annualised |
9.44 |
13.23 |
|
- Diluted - Not annualised |
2.31 |
- |
|
Annualised |
9.24 |
12.99 |
18 |
Aggregate of Non Promoters' Shareholding |
|
|
|
Number of shares - Face value of Rs.2 / - each. |
68750750 |
68750750 |
|
Percentage of Shareholding |
44.75% |
44.75% |
| |
| Segment Information : |
| |
Segment Revenue : |
|
|
| |
- Pharmaceuticals |
3,518.76 |
10,132.88 |
| |
- Medical Supplies |
559.82 |
1,611.53 |
| |
Less: Inter segment Revenue |
(150.54) |
(158.26) |
| |
Net Segment Revenue |
3,928.04 |
11,586.15 |
| |
|
|
|
| |
Segment Results : |
|
|
| |
Profit before tax and interest from each segment |
|
|
| |
- Pharmaceuticals |
603.66 |
1,212.35 |
| |
- Medical Supplies |
23.17 |
75.90 |
| |
Total |
626.83 |
1,288.25 |
| |
Less: Interest |
(129.54) |
(268.84) |
| |
Other unallocable Income /(Expenditure) |
(102.96) |
1,362.31 |
| |
Total Profit before tax |
394.33 |
2,381.72 |
| |
|
|
|
| |
Capital Employed : |
|
|
| |
- Pharmaceuticals |
|
7,840.72 |
| |
- Medical Supplies |
|
178.68 |
| |
- Unallocable |
|
14,614.55 |
| |
Total Capital Employed |
|
22,633.95 |
|
Notes :
| 1 |
The above results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 10th June 06. |
| 2 |
The above results include the financials of Subsidiaries - Docpharma NV (w.e.f. 8th July 2005), Mchem Group, China (w.e.f. 16th January 2006 ) and Concord Biotech Limited, India.(w.e.f. 14th February 2006) and Joint Ventures - Astrix Laboratories Limited, India (w.e.f. 30th December 2005), Fine Chemical Corporation, South Africa (w.e.f. 1st January 2006). |
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 10th June 2006 |
Sd/-
N. PRASAD
Executive Chairman |
|
|
